Clinical characteristics and incidence of methotrexate-related lymphoproliferative disorders of patients with rheumatoid arthritis

Modern Rheumatology

Volumn 24, Issue 5, 2014, Pages 763-765

  Yoshida, Yuji ^a   Takahashi, Yuko ^b   Yamashita, Hiroyuki ^b   Kano, Toshikazu ^b   Kaneko, Hiroshi ^b   Mimori, Akio ^b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Incidence; Lymphoproliferative disorder; Methotrexate; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETANERCEPT; INFLIXIMAB; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISONE; RITUXIMAB; SOLUBLE INTERLEUKIN 2 RECEPTOR; TOCILIZUMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; INCIDENCE; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTPATIENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; T CELL LYMPHOMA; TREATMENT DURATION; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; LYMPHOPROLIFERATIVE DISORDERS; MIDDLE AGED;

AGED; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; INCIDENCE; LYMPHOPROLIFERATIVE DISORDERS; MALE; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84906314177     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2013.878016     Document Type: Article

References (17)

1. Gaulard P, Swerdlow S.H, Harris N.L, Jaff e ES, Sundstrom C. Other iatrogenic immunodefi ciency associated lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, Jaff e ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds.). WHO Classifi cation of Tumors of the Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: International Agency for Research on Cancer, 2008. pp. 350-1.
2. Salloum R, Cooper DL, Howe G, Lacy J, Tallini G, Crouch J, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrezate for Rheumatoid Arthritis and other rheumatic diseases. J Clin Oncol. 1996;14(6):1943-9.
3. Tokuhir AM, Watanabe R, Nemoto T, Sagaw AM, Tomikawa T, Tamaru J, et al. Clinicopathological analyses in patients with other iatrogenic immunodefi ciency-Associated lymphoproliferative diseases and rheumatoid arthritis. Leuk Lymphoma. 2012: 53(4): 616-23.
4. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classifi cation of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-324.
5. Matsuda T, Marugame T, Kamo KI, Katanoda K, Ajiki W, Sobue T;Japan Cancer Surveillance Research Group. Cancer incidence and incidence rates in Japan in 2005: Based on data from 12 populationbased cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2011;41(1):139-47.
6. Kingsmore SF, Hall BD, Allen NB, Rice JR, Caldwell DS. Association of methotrexate, rheumatoid arthritis and lymphoma: Report of 2 cases and literature review. J Rheumatol 1992; 19(9): 1462-5.
7. Bachman TR, Sawitzke AD, Perkins SL, Ward JH, Cannon GW. Methotrexate-Associated lymphoma in patients with rheumatoid arthritis: Report of two cases. Arthritis Rheum 1996;39(2):325-9.
8. Niitsu N, Okamoto M, Nakamine H, Hirano M. Clinicopathologic correlations of diff use large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexate. Cancer Sci 2010;101(5):1309-13.
9. Rizzi R, Curci P, Deli AM, Rinaldi E, Chiefa A, Specchia G, Liso V. Spontaneous remission of " methotrexate-Associated lymphoproliferative disorders " after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature. Med Oncol. 2009;26(1):1-9.
10. Bernatsky S, Clarke AE, Suissa S. Hematologic malignant neoplasms after drug exposure in Rheumatoid Arthritis. Arch Intern Med. 2008;168(4):378-81.
11. Wolfe F, Michaud K. Lymphoma in Rheumatoid Arthritis. A rthritis Rheum. 2004;50(6):1740-51.
12. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic infl ammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2010;54(3):692-701.
13. Asten P, Barrett J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol. 1999;26(8):1705-14.
14. Askling J, Fored C.M, Baecklund E, Brandt L, Backlin C, Ekbom A, et al. Haematopoietic malignancies in rheumatoid arthritis: Lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64(10):1414-20.
15. Salloum E, Cooper DL, Howe G, Lacy J, Tallini G, Crouch J, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 1996;14:1943-1949.
16. Hoshida Y, Xu JX, Fujita S, Nakamichi I, Ikeda J, Tomita Y, et al. Lymphoproliferative disorders in Rheumatoid arthritis: Clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol. 2007;34:322-40.
17. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic infl ammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006:54:692-701.